A. Cosimi, R. Colvin, and R. Burton, Use of Monoclonal Antibodies to T-Cell Subsets for Immunologic Monitoring and Treatment in Recipients of Renal Allografts, New England Journal of Medicine, vol.305, issue.6, pp.308-322, 1981.
DOI : 10.1056/NEJM198108063050603

A. Webster, T. Pankhurst, and F. Rinaldi, Monoclonal and Polyclonal Antibody Therapy for Treating Acute Rejection in Kidney Transplant Recipients: A Systematic Review of Randomized Trial Data, Transplantation, vol.81, issue.7, pp.953-65, 2006.
DOI : 10.1097/01.tp.0000215178.72344.9d

L. Chatenoud and J. Bluestone, CD3-specific antibodies: a portal to the treatment of autoimmunity, Nature Reviews Immunology, vol.27, issue.8, pp.622-654, 2007.
DOI : 10.1038/nri2134

J. Soulillou, P. Peyronnet, L. Mauff, and B. , PREVENTION OF REJECTION OF KIDNEY TRANSPLANTS BY MONOCLONAL ANTIBODY DIRECTED AGAINST INTERLEUKIN 2, The Lancet, vol.329, issue.8546, pp.1339-1381, 1987.
DOI : 10.1016/S0140-6736(87)90648-9

J. Soulillou, D. Cantarovich, L. Mauff, and B. , Randomized Controlled Trial of a Monoclonal Antibody against the Interleukin-2 Receptor (33B3.1) as Compared with Rabbit Antithymocyte Globulin for Prophylaxis against Rejection of Renal Allografts, New England Journal of Medicine, vol.322, issue.17, pp.1175-82, 1990.
DOI : 10.1056/NEJM199004263221702

J. Bluestone, W. Liu, and J. Yabu, The Effect of Costimulatory and Interleukin 2 Receptor Blockade on Regulatory T Cells in Renal Transplantation, American Journal of Transplantation, vol.8, issue.10, pp.2086-96, 2008.
DOI : 10.1111/j.1600-6143.2008.02377.x

B. Bielekova, M. Catalfamo, and S. Reichert-scrivner, Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R??-targeted therapy (daclizumab) in multiple sclerosis, Proceedings of the National Academy of Sciences, vol.103, issue.15, pp.5941-5947, 2006.
DOI : 10.1073/pnas.0601335103

D. Brennan, J. Daller, K. Lake, D. Cibrik, D. Castillo et al., Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplantation, New England Journal of Medicine, vol.355, issue.19, pp.1967-77, 2006.
DOI : 10.1056/NEJMoa060068

R. Calne, P. Friend, and S. Moffatt, Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients, The Lancet, vol.351, issue.9117, pp.1701-1703, 1998.
DOI : 10.1016/S0140-6736(05)77739-4

G. Ciancio and G. Burke, Alemtuzumab (Campath-1H) in Kidney Transplantation, American Journal of Transplantation, vol.7, issue.1, pp.15-20, 2008.
DOI : 10.1111/j.1600-6143.2007.02053.x

A. Muthusamy, A. Vaidya, and S. Sinha, Alemtuzumab Induction and Steroid-Free Maintenance Immunosuppression in Pancreas Transplantation, American Journal of Transplantation, vol.9, issue.10, pp.2126-2157, 2008.
DOI : 10.1111/j.1600-6143.2008.02373.x

J. Pascual, J. Pirsch, and J. Odorico, Alemtuzumab Induction and Antibody-Mediated Kidney Rejection After Simultaneous Pancreas-Kidney Transplantation, Transplantation, vol.87, issue.1, pp.125-157, 2009.
DOI : 10.1097/TP.0b013e31818c6db0

M. Pescovitz, Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of Action, American Journal of Transplantation, vol.20, issue.Suppl 11, pp.859-66, 2006.
DOI : 10.1111/j.1600-6143.2006.01288.x

H. Yi, J. Zhang, and Y. Zhao, The effects of antibody treatment on regulatory CD4+CD25+ T cells, Transplant Immunology, vol.19, issue.1, pp.37-44, 2008.
DOI : 10.1016/j.trim.2007.12.001

H. Yi, Y. Zhen, C. Zeng, L. Zhang, and Y. Zhao, Depleting Anti-CD4 Monoclonal Antibody (GK1.5) Treatment: Influence on Regulatory CD4+CD25+Foxp3+ T Cells in Mice, Transplantation, vol.85, issue.8, pp.1167-74, 2008.
DOI : 10.1097/TP.0b013e31816a1242

N. Monk, R. Hargreaves, and J. Marsh, Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade, Nature Medicine, vol.9, issue.10, pp.1275-80, 2003.
DOI : 10.1038/nm931

T. Kawai, A. Cosimi, and T. Spitzer, HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression, New England Journal of Medicine, vol.358, issue.4, pp.353-61, 2008.
DOI : 10.1056/NEJMoa071074

J. Dantal, E. Ninin, and M. Hourmant, ANTI-CD4 MoAb THERAPY IN KIDNEY TRANSPLANTATION-A PILOT STUDY IN EARLY PROPHYLAXIS OF REJECTION1, Transplantation, vol.62, issue.10, pp.1502-1508, 1996.
DOI : 10.1097/00007890-199611270-00020

Y. Van-oosterhout, L. Van-emst, and A. Schattenberg, A combination of anti-CD3 and anti- CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease, Blood, vol.95, pp.3693-701, 2000.

F. Vincenti, R. Mendez, and M. Pescovitz, A Phase I/II Randomized Open-Label Multicenter Trial of Efalizumab, a Humanized Anti-CD11a, Anti-LFA-1 in Renal Transplantation, American Journal of Transplantation, vol.157, issue.53, pp.1770-1777, 2007.
DOI : 10.1034/j.1399-0012.2001.150208.x

S. Faguer, N. Kamar, and C. Guilbeaud-frugier, Rituximab Therapy for Acute Humoral Rejection After Kidney Transplantation, Transplantation, vol.83, issue.9, pp.1277-80, 2007.
DOI : 10.1097/01.tp.0000261113.30757.d1

B. Nashan, R. Moore, and P. Amlot, Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients, The Lancet, vol.350, issue.9086, pp.1193-1201, 1997.
DOI : 10.1016/S0140-6736(97)09278-7

C. Haug, R. Colvin, and F. Delmonico, A PHASE I TRIAL OF IMMUNOSUPPRESSION WITH ANTIIC AM-1 (CD54) mAb IN RENAL ALLOGRAFT RECIPIENTS, Transplantation, vol.55, issue.4, pp.766-73, 1993.
DOI : 10.1097/00007890-199304000-00016

F. Vincenti, C. Larsen, and A. Durrbach, Costimulation Blockade with Belatacept in Renal Transplantation, New England Journal of Medicine, vol.353, issue.8, pp.770-81, 2005.
DOI : 10.1056/NEJMoa050085

H. Xu, D. Tadaki, and E. Elster, Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates, Transplantation, vol.74, issue.7, pp.940-943, 2002.
DOI : 10.1097/00007890-200210150-00007

J. Thompson, C. Pomeroy, and R. Kryscio, Use of a T cell-specific monoclonal antibody, T10B9, in a novel allogeneic stem cell transplantation protocol for hematologic malignancy high-risk patients, Biology of Blood and Marrow Transplantation, vol.10, issue.12, pp.858-66, 2004.
DOI : 10.1016/j.bbmt.2004.09.006

T. Zhang, B. Nguyen, and G. Wu, Efficacy of a novel non-activating anti- CD28 scFv Ab in cynomolgus monkey cardiac allotransplantation. Oral presentation, World Transplant Congress, 2006.

N. Poirier, C. Mary, and E. Allain-launay, Immunomodulation induced by a CD28 antagonist in kidney allograft baboon recipient. Oral presentation, World Transplant Congress, 2008.

B. Blazar, R. Levy, and T. Mak, CD30/CD30 Ligand (CD153) Interaction Regulates CD4+ T Cell-Mediated Graft-versus-Host Disease, The Journal of Immunology, vol.173, issue.5, pp.2933-2974, 2004.
DOI : 10.4049/jimmunol.173.5.2933

A. Imai, T. Suzuki, and A. Sugitani, A Novel Fully Human Anti-CD40 Monoclonal Antibody, 4D11, for Kidney Transplantation in Cynomolgus Monkeys, Transplantation, vol.84, issue.8, pp.1020-1028, 2007.
DOI : 10.1097/01.tp.0000286058.79448.c7

A. Lazarovits, S. Poppema, and Z. Zhang, Prevention and reversal of renal allograft rejection by antibody against CD45RB, Nature, vol.380, issue.6576, pp.717-737, 1996.
DOI : 10.1038/380717a0

H. Gassel, C. Otto, and A. Gassel, TOLERANCE OF RAT LIVER ALLOGRAFTS INDUCED BY SHORT-TERM SELECTIVE IMMUNOSUPPRESSION COMBINING MONOCLONAL ANTIBODIES DIRECTED AGAINST CD25 AND CD54 WITH SUBTHERAPEUTIC CYCLOSPORINE1, Transplantation, vol.69, issue.6, pp.1058-67, 2000.
DOI : 10.1097/00007890-200003270-00008

J. Woodward, A. Bayer, and K. Chavin, ANTI-TRANSFERRIN RECEPTOR MONOCLONAL ANTIBODY, Transplantation, vol.65, issue.1, pp.6-9, 1998.
DOI : 10.1097/00007890-199801150-00003

U. Hartwig, M. Nonn, and S. Khan, Depletion of Alloreactive Donor T Lymphocytes by CD95-Mediated Activation-Induced Cell Death Retains Antileukemic, Antiviral, and Immunoregulatory T Cell Immunity, Biology of Blood and Marrow Transplantation, vol.14, issue.1, pp.99-109, 2008.
DOI : 10.1016/j.bbmt.2007.10.002

B. Chung, E. Dudl, and D. Min, Prevention of graft-versus-host disease by anti IL-7Ralpha antibody, Blood, vol.110, pp.2003-2013, 2007.

X. Yuan, A. Salama, and V. Dong, The Role of the CD134-CD134 Ligand Costimulatory Pathway in Alloimmune Responses In Vivo, The Journal of Immunology, vol.170, issue.6, pp.2949-55, 2003.
DOI : 10.4049/jimmunol.170.6.2949

H. Cho, B. Kwon, and H. Yagita, Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival, Transplant International, vol.171, issue.7, pp.351-61, 2004.
DOI : 10.1172/JCI200317662

R. Gorczynski, L. Lee, and I. Boudakov, Augmented Induction of CD4+CD25+ Treg using Monoclonal Antibodies to CD200R, Transplantation, vol.79, issue.9, pp.1180-1183, 2005.
DOI : 10.1097/01.TP.0000152118.51622.F9

C. Guillonneau, V. Aubry, and K. Renaudin, Inhibition of Chronic Rejection and Development of Tolerogenic T Cells after ICOS-ICOSL and CD40-CD40L Co-stimulation Blockade, Transplantation, vol.80, issue.4, pp.255-63, 2005.
DOI : 10.1097/01.TP.0000165429.57421.D6

X. Pan, L. Guo, and Y. Deng, Further study of anti-ICOS immunotherapy for rat cardiac allograft rejection, Surgery Today, vol.193, issue.8, pp.815-840, 2008.
DOI : 10.1007/s00595-007-3734-y